The U.S. Patent Trial and Appeal Board invalidated Exact Sciences’ patent covering a key component of its Cologuard colorectal cancer screening assay following a challenge by Geneoscopy. The PTAB found all claims of patent US11,634,781 unpatentable due to obviousness against prior art, supporting Geneoscopy’s position against infringement allegations. Geneoscopy’s FDA-approved ColoSense test detects RNA and hemoglobin markers in stool and offers an alternative CRC screening method. Exact Sciences disputes the ruling and intends to continue pursuing patent infringement litigation in federal court. This decision highlights ongoing patent disputes shaping the competitive landscape of non-invasive colorectal cancer diagnostics.